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The agonists of toll-like receptors (TLRs)
have been actively pursued for their anti-
tumor potentials, either as monotherapy
or as adjuvants to vaccination or other
therapeutic modalities (1). A search on
ClinicalTrials.gov using the key words
“TLR” and “cancer” returned 34 listings.
The idea of using TLR agonist to pro-
vide a “danger signal” and break toler-
ance to tumor antigens has been well
embraced by tumor immunologists. How-
ever, the promise of TLR agonists-based
immunotherapy remains to be realized in
the clinic, and only very few TLR agonists
have been approved by the FDA. For exam-
ple, bacillus Calmette–Guerin (BCG) and
imiquimod have been approved as stand-
alone therapies, whereas monophosphoryl
lipid A (MPL) was approved as a vaccine
component. A review of recently published
literature on the use of TLR agonists in can-
cer setting revealed a common mechanism
that might have explained the underper-
formance of TLR agonists as cancer ther-
apeutics: induction of immune suppres-
sive factors that put a break on the TLR
agonists-induced inflammation. As shown
in Figure 1, TLR agonists have immune
stimulatory effects through the induction
of costimulatory molecules (CD80, CD86,
and CD40) on dendritic cells (DCs) and
inflammatory cytokines (TNF-α and IL-
12) that polarize Th1 immune response.
On the other hand, TLR agonists have
immune inhibitory effects as evidenced by
the induction of several immune suppres-
sive factors, including IL-10, T regulatory
cells (Treg), and PD-L1, all of which could
dampen anti-tumor immunity. The follow-
ing is a brief summary on TLR agonists-
induced self-regulatory feedback and the
indication for cancer immunotherapy.
INDUCTION OF IL-10
IL-10 is an immune suppressive cytokine
that inhibits the activity of Th1 cells, thus
impeding viral clearance and anti-tumor
Th1 immunity. IL-10 could be secreted
by different immune cells, including Treg
(2), CD4 T cells (3, 4), monocytes, and
macrophages (5). The induction of IL-10
by TLR agonists has been demonstrated in
infectious disease setting as well as tumor
setting. For example, TLR4 signaling with
LPS was shown to activate innate IL-10 pro-
duction in response to Bordetella pertussis,
which both directly, and by promoting the
induction of IL-10-secreting type 1 regu-
latory T cells (Tr1), inhibit Th1 responses
and limit inflammatory pathology in the
lungs during infection with B. pertussis (6).
TLR2 ligation and induction of IL-10 were
also shown to suppress immunity against
Candida albicans (7). Induction of IL-10
also caused the persistence of lympho-
cytic choriomeningitis virus (LCMV), and
IL-10 blockade using a neutralizing anti-
body can restore T cell immunity and lead
to viral clearance (3). IL-10 induction by
TLR agonists has been observed in mouse
models of breast cancer and melanoma.
In MMTV/neu-transgenic mice, a model
of human HER2+ breast cancer, topical
treatment with TLR7 agonist imiquimod
induced IL-10, and the major source of
IL-10 was Tr1 cells (4). IL-10 induction
was also observed in a mouse model of
implanted TSA breast cancer, where top-
ical imiquimod was shown to synergize
with radiation and low-dose cyclophos-
phamide in inhibiting tumor growth (8).
In a mouse model of B16 melanoma, the
induction of IL-10 has also been shown to
limit the anti-tumor effects of TLR2 ago-
nist Pam2 lipopeptide (9). Altogether these
publications suggest IL-10 induction is
probably a common regulatory mechanism
that dampens TLR agonists-induced anti-
tumor immunity. IL-10 blockade using
anti-IL-10 neutralizing mAb significantly
enhanced the anti-tumor effects of topi-
cal imiquimod (4). The addition of anti-
IL-10R to TLR9 agonist CpG also exhib-
ited robust anti-tumor activity exceeding
by far that of CpG alone, and elicited anti-
tumor immune memory (10). Thus IL-10
blockade holds promise to augment the
anti-tumor effects of TLR agonists.
INDUCTION OF Treg
Although some early studies have reported
that TLR agonists could inhibit the func-
tion or number of Treg (11), more recent
studies have demonstrated that TLR ago-
nists can increase Treg number and func-
tion. For example, TLR2 ligation has been
shown to promote the survival of Treg
(12). Treatment of prediabetic mice with
a synthetic TLR2 agonist diminished type
1 diabetes and increased the number and
function of Treg, also conferring DCs with
tolerogenic properties (13). TLR2 agonist
Pam3Cys was also shown to induce Treg
expansion in the lungs and result in long-
term protection against manifestation of
allergic asthma in mice (14). Human plas-
macytoid DC activated by TLR9 ago-
nist CpG has been shown to induce the
generation of Treg (15). Another study
reported that TLR agonists-stimulated
allogeneic pDCs induces CD8+ Tregs that
inhibit allogeneic T cell responses, includ-
ing memory T cells (16). Studies from
our group demonstrated that TLR7 ago-
nist imiquimod induces Tregs, either as
monotherapy or as an adjuvant to vacci-
nation (4, 17). Treg was induced in both
www.frontiersin.org March 2014 | Volume 5 | Article 83 | 1
Lu TLR agonists for cancer immunotherapy
FIGURE 1 | Schematic diagram showing that PD-1/PD-L1 blockade may enhanceTLR-based
immunotherapy by tipping the balance between the immune stimulatory and inhibitory effects of
TLR agonists. Treatment with TLR agonists in tumor-bearing host not only induces pro-inflammatory
anti-tumor responses but also induce anti-inflammatory factors (IL-10, Treg, and PD-L1) that dampen
anti-tumor immune responses.
the periphery and the tumor microen-
vironment (4). Another study showed
that imiquimod enhanced the suppres-
sor function of Treg cells by sensitiz-
ing Treg cells to IL-2-induced activation
(18). A study on transcutaneous vaccina-
tion using imiquimod as adjuvant showed
that Treg and IL-10 act independently to
counter-regulate the cytotoxic T lympho-
cytes (CTL) response induced by vaccina-
tion (19). When TLR9 agonist CpG was
used as adjuvant to protein vaccination,
antigen-specific Treg was induced (20).
The ability of CpG to induce Treg has
been shown to be mediated by p38 MAPK
and inhibition of p38 in DC was shown
to attenuate Treg induction by TLR ago-
nists and enhance their efficacy as vaccine
adjuvants and cancer immunotherapeutics
(21). Thus inhibiting Treg induction repre-
sents another opportunity to augment the
anti-tumor effects of TLR agonists.
INDUCTION OF PD-L1
PD-L1 (also known as B7-H1 or CD274) is
a B7-related protein that inhibits T cell acti-
vation via engaging the programed death-1
(PD-1) receptor that is expressed on acti-
vated T cells. PD-L1 can be expressed on
tumor cells as well as hematopoietic cells.
The induction of PD-L1 by TLR ligation
has been reported for different TLR ago-
nists, in both in vitro and in vivo studies.
For example, TLR7/8 agonist resiquimod
and TLR4 agonist LPS have been shown
to induce PD-L1 on DC and contribute
to the development of tolerogenic APCs
(22). TLR4 ligation by MPL was also shown
to enforce the tolerogenic properties of
oral mucosal Langerhans cells (23). Topi-
cal imiquimod was shown to induce PD-
L1 as well as CD86 in different subsets
of skin DC (24). Another study showed
that TLR4 agonist LPS and TLR7/8 ago-
nist CL097 induced PD-L1 expression on
macrophages and the induction appeared
to be dependent on IL-10 (25). Induction
of PD-L1 has been linked to the lack of
protective immunity to bacteria (26). In
mouse tumor models, the induction of PD-
L1 has also been shown to be an important
mechanism that limits the anti-tumor effi-
cacy of TLR agonists (27, 28). The TLR3
agonist poly I:C up-regulated PD-L1 on
DC, and depletion or blockade of PD-L1
on activated DCs increased the magnitude
of effector CD8 T cell expansion (28). PD-
L1 also collaborates with Treg to impair the
recall responses of tumor-specific memory
T cells (27). Combination of PD-L1 block-
ade, CD4 T cell depletion, and tumor cell
vaccination resulted in complete regression
of large established RENCA tumors and
established long-lasting protective immu-
nity (27). Thus, blocking PD-1/PD-L1 sig-
naling represents another opportunity to
augment the anti-tumor effects of TLR
agonists.
It should be noted that the list above is
not exhaustive. Other immune suppressive
factors such as TGF-beta (TGF-β), mostly
notably secreted from Treg, could also be
induced after TLR agonist treatment, espe-
cially with agonists of TLR2 and TLR4
(13, 29). It should also be noted that the
various immune suppressive factors listed
above don’t function separately but in an
interactive manner. For example, induc-
tion of PD-L1 is crucial to the induction
of Treg (30), and the induction of PD-L1
has been shown to be dependent on IL-10
(25). TLR ligation could induce these dif-
ferent suppressive factors simultaneously,
and blocking one factor may decrease the
other factors as well.
In summary, the immune responses are
highly controlled. Once a T cell response
is initiated, it needs to be dampened
to prevent collateral damage. TLR liga-
tion not only initiates immune response,
but also triggers negative regulatory path-
ways. The above discussion about TLRs
is equally true for the normal existent
immune response to cancer as well as can-
cer vaccine-induced response. The induc-
tion of these regulatory pathways repre-
sents a major obstacle in developing TLR
agonists as cancer immunotherapeutics,
and the promise of using TLR agonists
to eradicate tumor cells probably won’t be
realized unless we block the negative regu-
lators (IL-10, Treg, and PD-L1, etc) and tip
the balance toward an overwhelming pro-
inflammatory response. Cancer immunol-
ogists are now exploring novel combina-
tional therapies that combine TLR liga-
tion with blockade of the negative regula-
tors. For example, the cancer immunother-
apy trial network (CITN) has considered a
pilot clinical trial testing the combination
of topical imiquimod and IL-10 blockade
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in breast cancer patients with chest wall
metastasis (per communication with Dr.
Martin Cheever, CITN director). Unfortu-
nately this idea did not move forward due
to the unavailability of anti-human IL-10
mAb. Currently a clinical trial combin-
ing topical imiquimod and PD-1/PD-L1
blockade for treating breast cancer cuta-
neous metastasis is also being planned in
the University of Washington.
The early data from clinical trials of
anti-PD-1 and anti-PD-L1 are harbingers
of a radical change in immunotherapy as
well as cancer therapy in general. Based
in large part on data from the check-
point inhibitor trials, it’s been predicted
that cancer immunotherapy will provide
the backbone of up to 60% of cancer ther-
apy within the next decade. There are at
least seven companies competing in the
anti-PD-1/PD-L1 space. The agents will be
tested with every conceivable combination.
Combinations with immunotherapies that
augment existent immune responses or
vaccine-induced immune responses, such
as TLR therapies will be tested soon with
anti-PD-1/PD-L1 and are highly likely to
be more effective in that context. Not only
will the blockade of PD-L1 signaling likely
enhance the immune stimulatory effects
of TLR agonists, but we also expect TLR
ligation to enhance the effect of PD-1/PD-
L1 blockade by increasing tumor infiltrat-
ing immune cells (TIL). The presence of
TIL has been associated with good clini-
cal response in the check-point blockade
therapy. In addition to anti-PD-1/PD-L1,
there will be other check-point inhibitors
that will also become available for testing
with TLR agonists. The world of cancer
immunotherapy is on a predictable course
to become a major component of cancer
therapy and TLR agonists will likely play
an important role.
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